6 
PROCEEDINGS 
The meeting was convened pursuant to notice at 9:00 a.m. , Dr. Donald S. 
Fredrickson, Director, NIH, presiding. 
DR. FREDRICKSON: Good morning. I am very glad to welcome all of you 
here today to provide us with your perspectives on a research activity of 
the National Institutes of Health that has very broad public policy 
implications . 
This is a special meeting of the Advisory Committee to the Director 
of the National Institutes of Health. At the time this meeting was organ- 
ized, that committee had but five members. Therefore, it was our pleasure 
to invite a number of former committee members, and other scientific and 
public representatives to participate in this special session. 
There is available on the table here a number of materials which in- 
clude several things that I would like to call to your attention. One 
is a statement from the Boston Group; several statements concerning the 
guidelines which all of you may wish to and should take advantage of the 
opportunity to see. Also there is a list of those who are members of the 
committee for the purposes of this meeting today. 
Since many of you do not have that, I think I might take this moment 
to simply identify the members who are sitting at the table here today. 
I really prefer that the chairman try to do that rather than ask each in- 
dividual to do it, at least as a test to see whether the chairman knows 
who is here. 
(Laughter. ) 
At my immediate left is Dr. Lamont -Haver s , who is the Deputy Director 
of the NIH. 
Next to him is Dr. Joseph Perpich, who is the Associate Director 
Designate for the Office of Program Planning and Evaluation at NIH. 
Skipping down to Dr. Robert Sinsheimer, who is Chairman of the Division 
of Biology at Cal Tech, and a molecular biologist. 
Next to him is Dr. Marjorie Shaw, who is from Houston, and Director of 
an Institute of Medical Genetics. She is both a geneticist and a lawyer. 
[ 147 ] 
